A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)

NCT01351792 | Terminated Phase 3

• 2 other identifiers: CCD-1007-PR-00452010-022895-30
• Study Type: interventional
• Target: 113
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the present study is to demonstrate the higher efficacy of small particles Foster® 100/6 (two puffs b.i.d.) versus large particles Symbicort® 200/6 (two inhalations b.i.d.), in terms of residual volume reduction over a 12-week treatment period in Chronic Obstructive Pulmonary Disease (COPD) patients.

Conditions

Chronic Obstructive Pulmonary Disease

Outcome Measures

Primary Outcomes (1)

• Change from baseline to end of treatment in post-dose residual volume.

  At day 84

Secondary Outcomes (11)

• Changes from baseline in FEV1, FVC, FEV1/FVC, IVC/FVC, RV, TLC, RV/TLC, FRC, FRC/TLC, RV/VC, Raw, eff and sGaw, eff.

  At day 84

• Changes from baseline in airways resistance (R5, R20, R5-20) and reactance at 5 Hertz (X5) (in a subset of at least 50% of patients from pre-selected sites);

  at day 84

• Changes from baseline in COPD symptom scores (for each single score and the total score);

  At day 84

• Change from baseline in percentage of COPD symptom-free days;

  At day 84

• Change from baseline in rescue salbutamol or ipratropium bromide consumption (puffs per day);

  At day 84

Study Arms (2)

Foster®

EXPERIMENTAL

Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP "extrafine" 400 µg plus FF 24 µg).

Drug: Foster® 100/6 µg/unit dose

Symbicort® Turbohaler®

ACTIVE COMPARATOR

Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).

Drug: Symbicort® Turbohaler® 200/6 μg/actuation

Interventions

Foster® 100/6 µg/unit dose DRUG

Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP "extrafine" 400 µg plus FF 24 µg).

Foster®

Symbicort® Turbohaler® 200/6 μg/actuation DRUG

Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).

Symbicort® Turbohaler®

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female patients aged ≥ 40 years, who have signed an Informed Consent form prior to initiation of any study-related procedure or when applicable written informed consent obtained by legal representative.
• Outpatients with a clinical diagnosis of moderate to severe COPD and including:
• Smoking history of at least 10 pack years defined as \[(number of cigarettes smoked per day) x (number of years of smoking)\] / 20, both current and ex-smokers are eligible.
• Regular use of bronchodilators (e.g. β2-agonist, anticholinergics) in the 2 months before visit 1.
• Post-bronchodilator FEV1 \< 65% of the predicted normal value at visit 1.
• Post-bronchodilator FEV1/FVC \< 0.7 at visit 1.
• An increase in FEV1 \< 15% and \< 200 mL from baseline following administration of 400 µg of salbutamol at visit 1.
• Plethysmographic Functional Residual Capacity (FRC) \> 120% of the predicted normal value (at visit 1 and visit 2).
• A Baseline Dyspnoea Index (BDI) focal score less or equal to 10 (at visit 1 and at visit 2).
• A cooperative attitude and ability to be trained to the proper use of pMDI and DPI (Turbohaler®, inspiratory flow-driven, multidose powder inhaler) inhalers.

You may not qualify if:

• Diagnosis of asthma or other clinically or functionally relevant respiratory disorders (other than COPD) which may interfere with data interpretation according to the investigator's opinion.
• Clinically unstable concurrent disease: e.g. hyperthyroidism, diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; cardiovascular disease (e.g. coronary artery disease, hypertension, heart failure); gastrointestinal disease (e.g. active peptic ulcer); neurological disease; haematological disease; autoimmune disorders, or other which may impact the evaluation of the results of the study according to investigator's judgement.
• Patients with COPD exacerbation and/or symptomatic infection of the airways requiring antibiotic therapy (at least 5 days) in the 2 months prior to screening and during the study period.
• Patients treated with depot corticosteroids in the 2 months preceding the visit 1 and during the run-in period.
• Major surgery in the previous 3 months and during the trial which may affect patient's compliance in study procedures (e.g. plethysmography).
• Patients requiring chronic mechanical ventilation for COPD.

Sponsors & Collaborators

• Chiesi Farmaceutici S.p.A.: lead

Study Sites (1)

Department of Pulmonary Diseases - University Medical Center Groningen

Groningen, 9713, Netherlands

Location

Related Publications (2)

• Faiz A, Imkamp K, van der Wiel E, Boudewijn IM, Koppelman GH, Brandsma CA, Kerstjens HAM, Timens W, Vroegop S, Pasma HR, Boersma WG, Wielders P, van den Elshout F, Mansour K, Steiling K, Spira A, Lenburg ME, Heijink IH, Postma DS, van den Berge M. Identifying a nasal gene expression signature associated with hyperinflation and treatment response in severe COPD. Sci Rep. 2020 Oct 15;10(1):17415. doi: 10.1038/s41598-020-72551-0.

  PMID: 33060632 DERIVED

• Boudewijn IM, Faiz A, Steiling K, van der Wiel E, Telenga ED, Hoonhorst SJM, Ten Hacken NHT, Brandsma CA, Kerstjens HAM, Timens W, Heijink IH, Jonker MR, de Bruin HG, Sebastiaan Vroegop J, Pasma HR, Boersma WG, Wielders P, van den Elshout F, Mansour K, Spira A, Lenburg ME, Guryev V, Postma DS, van den Berge M. Nasal gene expression differentiates COPD from controls and overlaps bronchial gene expression. Respir Res. 2017 Dec 21;18(1):213. doi: 10.1186/s12931-017-0696-5.

  PMID: 29268739 DERIVED

Related Links

• Study Record on EU Clinical Trials Register including results

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Foster Home Care

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Patient Care; Therapeutics; Community Health Services; Health Services; Health Care Facilities Workforce and Services

Study Officials

• Dirkje Postma, MD

  Dept. of Pulmonary Medicine and Tuberculosis - University of Groningen - The Netherlands

  STUDY CHAIR

• Marteen van den Berge, MD

  Dept. of Pulmonary Medicine and Tuberculosis - University of Groningen - The Netherlands

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 10, 2011
• First Posted: May 11, 2011
• Study Start: September 1, 2011
• Primary Completion: November 1, 2012
• Study Completion: November 1, 2012
• Last Updated: March 30, 2017

Record last verified: 2017-03

Locations

NL (1)